Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Butylscopolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 6/20 | 0.96 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.74 |
| ▸ | BLM | P54132 | 6/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.96 |
| ▸ | TSHR | P16473 | 2/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.96 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.77 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylscopolamine SCHEMBL10732782 | 0.99 | BLM (0.96) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL29373202 | 0.99 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL25291 | 0.99 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL2441812 | 0.99 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL25292 | 0.99 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL1650352 | 0.99 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL14672547 | 0.98 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL29473416 | 0.98 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL16168163 | 0.98 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL2446869 | 0.98 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210289832-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3849347-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210213091-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210145036-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | Poviva Corp. | 2021-05-20 | — | — | US | disclosed |
| US-20210145841-A1 | ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Poviva Corp. | 2021-05-20 | — | — | US | disclosed |
| EP-3810135-A1 | ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Poviva Corp. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3780976-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | Poviva Corp. (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20210045998-A1 | TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS | Poviva Corp. | 2021-02-18 | — | — | US | disclosed |
| EP-3765088-A1 | TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS | Poviva Corp. (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200178572-A1 | MICROWAVE PROCESSING METHODS FOR FORMULATING ORALLY INGESTIBLE COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE AGENTS | Poviva Corp. | 2020-06-11 | — | — | US | disclosed |
| WO-2020056344-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | POVIVA TEA, LLC (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2019204502-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | POVIVA TEA, LLC (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019178360-A1 | TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS | POVIVA TEA, LLC (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2018232422-A1 | MICROWAVE PROCESSING METHODS FOR FORMULATING ORALLY INGESTIBLE COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE AGENTS | POVIVA TEA, LLC (US) | 2018-12-20 | — | — | WO | disclosed |
| US-9707220-B2 | Scopolamine for the treatment of depression and anxiety | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-07-18 | — | — | US | disclosed |
| US-20140378501-A1 | SCOPOLAMINE FOR THE TREATMENT OF DEPRESSION AND ANXIETY | The Governmen of the United States of America, as represented by Secretary, Department of Health and (US) | 2014-12-25 | — | — | US | disclosed |
| US-8859585-B2 | Scopolamine for the treatment of depression and anxiety | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-14 | — | — | US | disclosed |
| EP-1896025-A1 | SCOPOLAMINE FOR THE TREATMENT OF DEPRESSION AND ANXIETY | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20060270698-A1 | Scopolamine for the treatment of depression and anxiety | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2006-11-30 | — | — | US | disclosed |
| WO-2006127418-A1 | SCOPOLAMINE FOR THE TREATMENT OF DEPRESSION AND ANXIETY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270698-A1 | Scopolamine for the treatment of depression and anxiety | CHRNA1, SLC18A3, CHRNB1 | CHRM2 10/4885CHRM3 7/4885BLM 575/4885 |
| US-20200178572-A1 | MICROWAVE PROCESSING METHODS FOR FORMULATING ORALLY INGESTIBLE COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE AGENTS | PNLIP, LIPC, LIPA | CHRM2 3221/4885CHRM3 4106/4885BLM 3648/4885 |
| US-20210045998-A1 | TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS | LIPA, MMP8, MMP1 | CHRM2 1704/4885CHRM3 1952/4885BLM 3109/4885 |
| US-20210145036-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | LIPC, PNLIP, LIPA | CHRM2 4015/4885CHRM3 4238/4885BLM 4567/4885 |
| US-20210145841-A1 | ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | FABP7, LIPA, LIPC | CHRM2 795/4885CHRM3 1329/4885BLM 2981/4885 |
| US-20140378501-A1 | SCOPOLAMINE FOR THE TREATMENT OF DEPRESSION AND ANXIETY | CHRNA1, CHRNA2, SLC18A3 | CHRM2 9/4885CHRM3 11/4885BLM 577/4885 |
| US-20210213091-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | MGLL, LIPA, LAMP1 | CHRM2 162/4885CHRM3 287/4885BLM 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.